Drug discovery laboratories struggle with process bottlenecks and poor efficiency of loading specific constructs into cells for cell based assays. Join this webinar and learn how the MaxCyte® STX™ Scalable Transfection System can overcome these challenges and improve the potential for yielding new drug candidates. Case studies will demonstrate the superior performance of the MaxCyte STX™ for loading cells with constructs such as ion channels and reporter systems for use in cell based assays.

The webinar will be led by John Reardon, Ph.D., formerly Senior Vice President of Discovery Research Biology at GlaxoSmithKline and now Chief Scientific Officer at Cardioxyl Pharmaceuticals. Two leading industry experts on cell transfections and ion channels will participate in the webinar: James Brady, Ph.D., Director of Technical Applications at MaxCyte, and Barbara A. Wible, Ph.D., Head of Cellular and Molecular Biology at ChanTest Corporation.

Dr. Barbara A. Wible is an industry expert in ion channel screens for drug discovery. Dr. Wible will discuss the use of MaxCyte® STX™ System to create ion channel cell lines for drug screening.

Dr. James Brady is an applications expert in cell based assays. Dr. Brady will present case studies on using the MaxCyte® STX™ System for cell based assay development.

Dr. John Reardon is a renowned thought leader in drug discovery. Dr. Reardon will discuss the importance of effective cell transfections to develop biologically relevant screening assays, and how the MaxCyte® STX™ System improves transfection efficiency.